THL/1110/2.02.06/2026 / Hepatitis B (HBV) vaccine for children and adults 2027-2029 (2029-2030,2030-2031)
Määräaika:
18.5.2026
12.00
(UTC+03:00)
Määräaikaan:
Tiivistelmä
Katso samankaltaisia mahdollisuuksia
Kaikkien tietojen näyttäminen vaatii rekisteröitymisen ja kirjautumisen palveluun.
THL/1110/2.02.06/2026 / Hepatitis B (HBV) vaccine for children and adults 2027-2029 (2029-2030,2030-2031)
Hankintailmoitustyyppi
Kilpailu [TED eF[16]]
Julkaistu
16.4.2026
6.09
(UTC+03:00)
Kysymysten jätön määräaika
27.4.2026
12.00
(UTC+03:00)
Tarjousten määräaika
18.5.2026
12.00
(UTC+03:00)
Organisaatio
Terveyden ja hyvinvoinnin laitos
Kuvaus
The Ministry of Social Affairs and Health (hereinafter ”STM”) and the Finnish Institute for Health and Welfare (hereinafter "THL" or “Customer” ) request your tender for Hepatitis B (HBV) Vaccine for children and adults included in the National Vaccination Programme in Finland.
The contract period is two (2) years during 2027-2029. The procurement contains two (2) one-year (1) contract period renewals (1+1) to extend the contract for 2029-2030 and 2030-2031.
Estimated quantity for the contract period including contract period renewals is 200.000 doses. Customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. On average THL delivers to wellbeing services counties/municipalities 35.000 +/- 5.000 doses for adults per year and 12.000 +/- 2000 doses for children per year (numbers are only rough estimations to help with allocating doses).
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The most economically advantageous Tender shall be a Tender with lowest total reference price for the competition.
Please note that all times given in the Call for tender refer to local time in Finland.
Call for Tenders, annexes:
Annex 1 Contract
Annex 2 JYSE 2025 SUPPLIES
Annex 3 Delivery schedule
Annex 4 Subcontractors
Annex 5 Description of the Handi Service
Annex 6 Bank details
Annex 7 Quality Agreement